U.S. Actinic Keratosis Treatment Market Size, Growth, Trends | Report 2023-2032
The U.S. actinic keratosis treatment market size was estimated at around USD 2.37 billion in 2022 and it is projected to hit around USD 3.22 billion by 2032, growing at a CAGR of 3.1% from 2023 to 2032.
Key Pointers
| Report Coverage | Details |
| Market Size in 2022 | USD 2.37 billion |
| Revenue Forecast by 2032 | USD 3.22 billion |
| Growth rate from 2023 to 2032 | CAGR of 3.1% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Companies Covered | Bausch Health Companies, Inc.; LEO Pharma A/S; Almirall, S.A; Biofrontera AG; GALDERMA; Sun Pharmaceutical Industries Ltd.; Novartis AG; Hill Dermaceuticals, Inc.; 3M; Viatris, Inc. |
The increasing prevalence of actinic keratosis, the increased risk of developing skin cancer, and the surge in the geriatric population of the country are the major driving growth factors. For instance, according to a report published in JAMA Dermatology, actinic keratosis affects around three of every 10 older Medicare recipients. Moreover, the presence of potential investigational candidates in the pipeline and the rising R&D efforts from pharmaceutical companies to develop novel treatment approaches for actinic keratosis are likely to contribute to market expansion over the forecast period.
According to the American Academy of Dermatology Association, more than 40 million Americans develop AK each year and the overall prevalence rate of AK in the U.S. is estimated to be about 26.5% in males and 10.2% in females. Factors such as severe baldness, the high tendency of sunburn, and skin wrinkling may increase the predisposition to AK in the male population. In addition, it is the most common pre-cancerous dermatological condition, around 5-10% of actinic keratosis can develop into Squamous cell carcinoma. Thus, the increasing prevalence of AK is anticipated to increase the treatment rate in the country.
Currently, treatment approaches such as home-based treatments with topical preparations, cryotherapy, and PDT are commonly employed to treat actinic keratosis. Moreover, several novel agents are under development phases to reduce adverse events, which is expected to increase the adoption rate of treatment of actinic keratosis. For instance, according to the NIH, some of the novel drugs being investigated for AK are resiquimod, betulinic acid, paclitaxel, potassium dobesilate, potassium hydroxide, and celecoxib. These therapeutic drugs are directed toward personalized treatment for patients having AK lesions as well as symptoms of cutaneous SCC.
In addition, the ongoing efforts to develop next-generation therapeutics for various dermatological disorders including AK, basal cell carcinoma, and atypical moles are expected to offer lucrative growth opportunities for the market. For instance, in October 2022, the Skin Cancer Foundation granted USD 125,000 to researchers to manage dermatological applications. This funding is mainly intended to promote innovation for the early detection and treatment of skin diseases such as AK.
Furthermore, higher rates of actinic keratosis treatment and increasing novel medicines usage in the country along with favorable initiatives from non-profit organizations to prevent actinic keratosis is a growth rendering factor for the market. For instance, in June 2021, the American Academy of Dermatology published new recommendations for the treatment of AK with its new GRADE approach. Moreover, according to Almirall’s presentation, the prescription of Klisyri in the U.S. AK topical market has increased by over 41,000 prescriptions since its launch.
However, most treatment options such as imiquimod, Solaraze, and Efudex have lost their patent exclusivities in the U.S., leading to the penetration of generics in the market. Genericization is expected to lower the revenue generation capacity of the market, thereby impeding market growth. Moreover, a stringent regulatory framework related to the safety and efficacy of drugs is further anticipated to reduce market growth over the forecast period.
U.S. Actinic Keratosis Treatment Market Segmentations:
By Therapy
By Drug Class
By Product
By End-use
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on U.S. Actinic Keratosis Treatment Market
5.1. COVID-19 Landscape: U.S. Actinic Keratosis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. U.S. Actinic Keratosis Treatment Market, By Therapy
8.1. U.S. Actinic Keratosis Treatment Market, by Therapy, 2023-2032
8.1.1. Topical/Drugs
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Surgery
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Photodynamic Therapy
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. U.S. Actinic Keratosis Treatment Market, By Drug Class
9.1. U.S. Actinic Keratosis Treatment Market, by Drug Class, 2023-2032
9.1.1. Nucleoside metabolic inhibitors
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Nonsteroidal anti-inflammatory drugs
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Immune response modifiers
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Photoenhancers
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. U.S. Actinic Keratosis Treatment Market, By Product
10.1. U.S. Actinic Keratosis Treatment Market, by Product, 2023-2032
10.1.1. 5-fluorouracil
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Diclofenac
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Imiquimod
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Tirbanibulin
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Capecitabine
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Aminolevulinic acid
10.1.6.1. Market Revenue and Forecast (2020-2032)
10.1.7. Porfimer sodium
10.1.7.1. Market Revenue and Forecast (2020-2032)
10.1.8. Others
10.1.9.1. Market Revenue and Forecast (2020-2032)
Chapter 11. U.S. Actinic Keratosis Treatment Market, By End-use
11.1. U.S. Actinic Keratosis Treatment Market, by End-use, 2023-2032
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Private clinics
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Homecare
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. U.S. Actinic Keratosis Treatment Market, Regional Estimates and Trend Forecast
12.1. U.S.
12.1.1. Market Revenue and Forecast, by Therapy (2020-2032)
12.1.2. Market Revenue and Forecast, by Drug Class (2020-2032)
12.1.3. Market Revenue and Forecast, by Product (2020-2032)
12.1.4. Market Revenue and Forecast, by End-use (2020-2032)
Chapter 13. Company Profiles
13.1. Bausch Health Companies, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. LEO Pharma A/S
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Almirall, S.A
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Biofrontera AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GALDERMA
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Sun Pharmaceutical Industries Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Novartis AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Hill Dermaceuticals, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. 3M
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Viatris, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers